antiretroviral

Diana Lockwood REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007 DIANA LOCKWOOD, London School of Hygiene and Tropical Medicine ICAAC delega

HOWARD MAYER, Pfizer Global Research, New London CT MARK WAINBERG, McGill University, Montreal Abstract Number: 104aLB, 104bLB, 14th Conference on Retroviruses and Opportunistic Infections, Los Angele

CHLOE THIO, Johns Hopkins University School of Medicine REFERENCE: Abstract: 136LB, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February 25-28, 2007 Entecavir, used to tr

STEVEN GRINSPOON, Massachusetts General Hospital, Boston COMMENT: JUDITH CURRIER, University of California, Los Angeles REFERENCE: 14th Conference on Retroviruses and Opportunistic Infections, Los Ang

RODGER MACARTHUR, Wayne State University, Detroit REFERENCE: Lancet 2006; 368: 2125-35 A three-class HIV antiretroviral therapy is not necessary, according to data published in the Lancet. The FIRST s

PAUL WEIDLE, Centers for Disease Control and Prevention, Atlanta REFERENCE: Lancet 2006; 368:1587-94 In rural sub-Saharan Africa there are many barriers to taking antiretroviral therapy successfully.

CHARLES HICKS, Associate Professor Medicine, Duke University, Durham REFERENCE: Lancet 2006; 368: 466-75 Results with a new antiretroviral agent, tipranavir, tested among patients who were resistant t